Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...
Cytiva will open a new 7,400m² manufacturing facility in Grens, Switzerland on May 31. The site will manufacture single use kits for the Sepax and Sefia cell processing systems, as well as consumables ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results